NCT00335166 is a Phase 3 clinical trial of Pardaprunox in Early Stage Parkinson Disease, sponsored by Solvay Pharmaceuticals.

Who is sponsoring NCT00335166?

NCT00335166 is sponsored by Solvay Pharmaceuticals.

What drugs are being tested in NCT00335166?

Interventions in NCT00335166: Pardaprunox, pramipexole, Placebo Comparator.

What condition does NCT00335166 study?

NCT00335166 studies Early Stage Parkinson Disease.

Is NCT00335166 still recruiting?

NCT00335166 is currently completed. Last updated 1 April 2008.

Last reviewed 2008-04-01 · How we verify

NCT00335166

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

Completed Phase 3 Last updated 1 April 2008

What this trial tests

Phase 3 trial testing Pardaprunox in Early Stage Parkinson Disease in 330 participants. Completed in 1 February 2008.

Timeline

1 November 2006

Primary endpoint
1 February 2008

1 February 2008

Quick facts

Lead sponsor	Solvay Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	330
Start date	1 November 2006
Primary completion	1 February 2008
Estimated completion	1 February 2008
Sites	89 locations across United States, Australia, Czechia, Estonia, France, Germany, India, Italy

Drugs / interventions tested

Pardaprunox — full drug profile →
pramipexole — full drug profile →
Placebo Comparator

Conditions studied

Early Stage Parkinson Disease — all drugs for Early Stage Parkinson Disease →

Sponsor

Solvay Pharmaceuticals — full company profile →

Who can join

30 and older, any sex, with Early Stage Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

UPDRS part 3 (motor score)and change from baseline to 24 weeks maintenance treatment
Time frame: 24 weeks

Sponsor's own description

This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.
Wong TS, Li G, Li S, Gao W, et al · · 2023 · cited 113× · PMID 37137892 · DOI 10.1038/s41392-023-01427-2

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00335166 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Solvay Pharmaceuticals
Last refreshed: 1 April 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00335166.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing